Identification of a novel GSK-3β inhibitor for Alzheimer’s disease using In-Silico prediction and experiment cycling, validated in a streptozotocin-induced Alzheimer’s disease mouse model
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-05 · 399 (8) · 11557-11579
DOI: 10.1007/s00210-026-05073-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 20.02.2026. Verfasst von Neha Chauhan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Banasthali Vidyapith, Banasthali, Rajasthan, 302022, India. Hauptthemen laut MEDLINE: Alzheimer Disease, Glycogen Synthase Kinase 3 beta, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
GSK-3β has been a key target in Alzheimer's disease (AD) research for over two decades. To identify novel GSK-3β inhibitors, 333 compounds from the National Cancer Institute (NCI) database were screened using a validated ligand-based pharmacophore model with four essential features (two hydrogen bond acceptors, one hydrophobic, and one aromatic ring). After tapering screening with refined boundaries, two top compounds (NSC 275 and NSC 3198) were identified. Molecular docking and simulation studies confirmed their strong binding affinity to GSK-3β. ELISA analysis revealed that their half maximal inhibitory concentration (IC50) values were comparable to the standard GSK-3β inhibitor, CHIR99021. Subsequent in-vivo studies assessed the efficacy of these chemical entities in tested mouse model. Acute toxicity studies demonstrated no observed adverse effect level (NOAEL). Whereas behavioral tests, using the Morris water maze, the tested compounds (5 mg/kg and 10 mg/kg) exhibited cognitive improvements comparable to those of the donepezil group (1 mg/kg), an approved AD treatment. Further analysis of oxidative stress, histopathology, and immune responses in the hippocampus (CA1) indicated that the NSC 275 and NSC 3198 reversed cognitive deficits similarly to the donepezil treated group. The results suggested that combination of in-silico, in-vitro, and in-vivo approaches demonstrates the potential of NSC 275 and NSC 3198 as promising GSK-3β inhibitors for AD treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Banasthali Vidyapith, Banasthali, Rajasthan, 302022, India.
- School of Pharmacy & Technology Management, SVKM's NMIMS, Shirpur, Maharashtra, 425405, India.
- Department of Pharmacognosy, United Institute of Pharmacy, Prayagraj, Uttar Pradesh, 211010, India.
- Department of Chemistry, Banasthali Vidyapith, Tonk, 302022, Rajasthan, India.
- Department of Pharmacy, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, 495009, India. achal.mishra03@gmail.com.
- Office of Research Administration, Chiang Mai University, Chiang Mai, 50200, Thailand. sudarshan.s@cmu.ac.th.
Zitieren
APA
Chauhan, N., Jain, S., Gupta, P., Dwivedi, J., Paliwal, S., Sharma, S., Mishra, A., Singh, S., Beth, M. R. M., & Arunraj, M. (2026). Identification of a novel GSK-3β inhibitor for Alzheimer’s disease using In-Silico prediction and experiment cycling, validated in a streptozotocin-induced Alzheimer’s disease mouse model. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(8), 11557-11579. https://doi.org/10.1007/s00210-026-05073-7
Vancouver
Chauhan N, Jain S, Gupta P, Dwivedi J, Paliwal S, Sharma S, et al. Identification of a novel GSK-3β inhibitor for Alzheimer’s disease using In-Silico prediction and experiment cycling, validated in a streptozotocin-induced Alzheimer’s disease mouse model. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(8):11557-11579. doi:10.1007/s00210-026-05073-7
BibTeX
@article{Chauhan2026,
author = {Chauhan, Neha and Jain, Smita and Gupta, Paras and Dwivedi, Jaya and Paliwal, Sarvesh and Sharma, Swapnil and Mishra, Achal and Singh, Sudarshan and Beth, Mini Rani Mary and Arunraj, Manjula},
title = {Identification of a novel GSK-3β inhibitor for Alzheimer’s disease using In-Silico prediction and experiment cycling, validated in a streptozotocin-induced Alzheimer’s disease mouse model},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
volume = {399},
number = {8},
pages = {11557--11579},
doi = {10.1007/s00210-026-05073-7}
}
EUVIMED